Related Experiment Video

Updated: Aug 24, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.3K

Differing strategies for sudden death prevention in hypertrophic cardiomyopathy

Martin S Maron1, Ethan Rowin2, Paolo Spirito3

  • 1Hypertrophic Cardiomyopathy Center, Lahey Medical Center, Burlington, Massachusetts, USA martin.maron@lahey.org.

Heart (British Cardiac Society)
|October 21, 2022
PubMed

Insights

Sudden death prevention in hypertrophic cardiomyopathy (HCM) has improved due to implantable cardioverter-defibrillators (ICDs) and risk stratification. However, differing international guidelines complicate risk assessment for sudden cardiac death (SCD) in HCM patients.

Area of Science:

  • Cardiology
  • Sudden Cardiac Death Research
  • Hypertrophic Cardiomyopathy Management

Background:

  • Sudden death (SD) is a primary concern in hypertrophic cardiomyopathy (HCM).
  • Advances in implantable cardioverter-defibrillators (ICDs) and risk stratification have significantly reduced HCM-related mortality.
  • Current HCM management faces challenges due to heterogeneous patient populations and varying risk assessment strategies.

Purpose of the Study:

  • To critically assess current strategies for preventing sudden death (SD) in hypertrophic cardiomyopathy (HCM).
  • To compare the strengths and weaknesses of divergent international risk stratification guidelines for SD in HCM.
  • To guide clinicians in managing SD risk within the context of differing cardiovascular society recommendations.

Main Methods:

  • Review of current literature on sudden death (SD) prevention in hypertrophic cardiomyopathy (HCM).
  • Comparative analysis of risk stratification algorithms and guidelines from major cardiovascular societies (AHA/ACC and ESC).
  • Critical evaluation of the sensitivity and specificity of different risk stratification approaches.

Main Results:

  • Primary prevention ICDs and refined risk stratification have lowered HCM mortality to approximately 0.5% annually.
  • Existing risk stratification strategies for SD in HCM are imperfect, varying in sensitivity and specificity.
  • Divergent guidelines from US and European societies create inconsistencies in SD risk assessment for HCM patients.

Conclusions:

  • While significant progress has been made in preventing sudden death (SD) in hypertrophic cardiomyopathy (HCM), challenges remain.
  • Clinicians must navigate differing international guidelines for risk stratification and management of SD in HCM.
  • Further refinement of risk assessment tools is needed to improve personalized SD prevention strategies in HCM.

Keywords:
Magnetic Resonance Imagingcardiomyopathy, hypertrophicdefibrillators, implantabletachycardia, ventricular

More Related Videos

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease12:15

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease

Published on: February 8, 2022

2.6K
Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

6.4K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
22
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
103